Longeveron Inc.
LGVN
NASDAQ·Healthcare·Biotechnology·Mkt cap $20.7M
$6.81
▲ +3.50%
P/E
-6.74
Mkt Cap
$20.7M
52-Wk Range
$4.75–$12.30
52-Week Range
$4.75 - $12.30
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Down 19.8% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Proprietary LOMECEL-B cell therapy platform with unique sourcing from young healthy donors
- Early-stage pipeline across multiple high-value disease indications
- Specialized expertise in regenerative medicine and cellular therapeutics
- Strategic positioning in the high-growth aging population treatment market
Bear Case
1 risk
- Low volatility (beta -0.3).
Growth
Moderate growth ahead
Advancement of Phase 1 and 2 clinical trials across multiple indications
Value
Valuation data unavailable
Momentum
Weak
-6.7% over 3m
Quality
Excellent
Mixed fundamentals
Dividend
None
No dividend
Smart-money signal
Who's buying LGVN right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 3, 2026
AUG 12, 2026
Reported EPS of -$0.19 vs -$0.18 consensus (-8.6% surprise). Revenue of $287.0K vs $326.0K expected (-12.0%).
EPS surprise · last 4Q
0 of 1 beats
Estimate
Actual
Q3 26
-8.6%
Revenue trend · last 8Q
—
—
-30%
-32%
-82%
-39%
+4%
-9%
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$773.0K
$603.0K
$381.0K
$316.0K
$137.0K
$365.0K
$398.0K
$287.0K
Margins · last 8Q
Gross
63.4%
Profit
-2116.0%
Wall Street consensus
2 analysts · 50% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
50%
Hold
50%
Sell
0%
Median Price Target
—
Latest: Maxim Group · May 11, 2026
vs Industry
How LGVN stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.